JP2012504135A - 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用 - Google Patents

経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用 Download PDF

Info

Publication number
JP2012504135A
JP2012504135A JP2011529277A JP2011529277A JP2012504135A JP 2012504135 A JP2012504135 A JP 2012504135A JP 2011529277 A JP2011529277 A JP 2011529277A JP 2011529277 A JP2011529277 A JP 2011529277A JP 2012504135 A JP2012504135 A JP 2012504135A
Authority
JP
Japan
Prior art keywords
composition
finasteride
acid
oil
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011529277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504135A5 (cg-RX-API-DMAC7.html
Inventor
エム. アリ,ショウカス
アーマド,アティーク
ユー. アーマド,モギス
シェイク,サイフディン
アーマド,イムラン
Original Assignee
ジャイナ ファーマシューティカルズ,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42060413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012504135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジャイナ ファーマシューティカルズ,インコーポレーテッド filed Critical ジャイナ ファーマシューティカルズ,インコーポレーテッド
Publication of JP2012504135A publication Critical patent/JP2012504135A/ja
Publication of JP2012504135A5 publication Critical patent/JP2012504135A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
JP2011529277A 2008-09-27 2009-09-25 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用 Pending JP2012504135A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10071408P 2008-09-27 2008-09-27
US61/100,714 2008-09-27
PCT/US2009/058463 WO2010036947A2 (en) 2008-09-27 2009-09-25 Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014130194A Division JP6196943B2 (ja) 2008-09-27 2014-06-25 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用

Publications (2)

Publication Number Publication Date
JP2012504135A true JP2012504135A (ja) 2012-02-16
JP2012504135A5 JP2012504135A5 (cg-RX-API-DMAC7.html) 2012-11-15

Family

ID=42060413

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011529277A Pending JP2012504135A (ja) 2008-09-27 2009-09-25 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
JP2014130194A Active JP6196943B2 (ja) 2008-09-27 2014-06-25 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
JP2016176561A Pending JP2017048188A (ja) 2008-09-27 2016-09-09 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014130194A Active JP6196943B2 (ja) 2008-09-27 2014-06-25 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
JP2016176561A Pending JP2017048188A (ja) 2008-09-27 2016-09-09 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用

Country Status (15)

Country Link
US (1) US9750812B2 (cg-RX-API-DMAC7.html)
EP (1) EP2344198B1 (cg-RX-API-DMAC7.html)
JP (3) JP2012504135A (cg-RX-API-DMAC7.html)
CA (1) CA2737025C (cg-RX-API-DMAC7.html)
CY (1) CY1123579T1 (cg-RX-API-DMAC7.html)
DK (1) DK2344198T3 (cg-RX-API-DMAC7.html)
ES (1) ES2834006T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201860T1 (cg-RX-API-DMAC7.html)
HU (1) HUE052571T2 (cg-RX-API-DMAC7.html)
LT (1) LT2344198T (cg-RX-API-DMAC7.html)
MX (1) MX2011003207A (cg-RX-API-DMAC7.html)
PL (1) PL2344198T3 (cg-RX-API-DMAC7.html)
PT (1) PT2344198T (cg-RX-API-DMAC7.html)
SI (1) SI2344198T1 (cg-RX-API-DMAC7.html)
WO (1) WO2010036947A2 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526483A (ja) * 2012-08-31 2015-09-10 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー. ポリマーフィナステリドナノ粒子、これを含有する水性組成物、脱毛症を治療するための組成物、前記組成物を調製するための方法、およびその使用
WO2016186157A1 (ja) * 2015-05-19 2016-11-24 株式会社メドレックス 経皮吸収型液剤
JPWO2015072564A1 (ja) * 2013-11-17 2017-03-16 株式会社 メドレックス 経皮吸収型コロイド液剤
JP2020527146A (ja) * 2017-07-12 2020-09-03 サムソン クリニカル プロプライエタリー リミテッド 育毛促進及び脱毛または過剰な毛髪脱落の治療
JP2022506944A (ja) * 2018-11-08 2022-01-17 ヴァーソナ セラピューティクス,インコーポレーテッド 5-α-レダクターゼ阻害剤の局所製剤及びそれらの使用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9861154B2 (en) 2008-07-18 2018-01-09 Biomod Collection Inc. Articles of manufacture releasing an active ingredient
US10633688B2 (en) 2010-09-24 2020-04-28 Follea International Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US8691518B2 (en) * 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
US9588118B2 (en) 2010-09-24 2017-03-07 Follea International Devices for performing colorimetric assay with plucked human hair
ITMI20102165A1 (it) * 2010-11-23 2012-05-24 Medichem Srl Composizione per il lavaggio dei capelli e del cuoio capelluto
EP2702982B1 (en) * 2011-04-25 2016-12-14 Jun-Hyoung Park Composition for topical application for preventing hair loss and stimulating hair growth
JP2015514683A (ja) * 2012-02-16 2015-05-21 ブライトサイド イノベーションズ,インコーポレイティド 食品性栄養組成物および使用方法
WO2013160896A1 (en) * 2012-04-25 2013-10-31 Hadasit Medical Research Services And Development Ltd. Pomegranate oil for preventing and treating neurodegenerative diseases
BR102012022036B1 (pt) * 2012-08-31 2019-10-01 Biolab Sanus Farmacêutica Ltda. Nanopartícula polimérica de finasterida e minoxidil, processo de sua preparação, suspensão aquosa contendo a mesma, composição farmacêutica, e seu uso
WO2014078929A1 (pt) * 2012-11-26 2014-05-30 Universidade Federal De Minas Gerais - Ufmg Formulações tópicas para a prevenção e tratamento da alopecia e para inibição do crescimento de pêlos
JP6595454B2 (ja) * 2013-05-03 2019-10-23 リピドール エービー 薬学的又は化粧学的活性成分を投与するための局部用組成物及びキャリアー
CA2921456C (en) 2013-08-15 2020-05-26 Mary Kay Inc. Topical skin compositions for treating wrinkles
US20150147382A1 (en) * 2013-09-23 2015-05-28 Exir Nano Sina Company Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same
US11660344B2 (en) 2013-11-17 2023-05-30 Medrx Co., Ltd. Transdermal colloidal solution agent
ES2952159T3 (es) * 2014-10-29 2023-10-27 Samson Clinical Pty Ltd Minoxidil oral para el tratamiento de alopecia areata
ES2765277T3 (es) 2014-12-22 2020-06-08 Reactive Reality Gmbh Método y sistema para generar datos de modelo de prenda
WO2016168236A1 (en) * 2015-04-13 2016-10-20 Fountain Technologies International, Llc One-step method for production of ultra-small lipid structures
JP7186093B2 (ja) 2016-04-19 2022-12-08 ナンヤン テクノロジカル ユニヴァーシティー 前眼部疾患の治療のためのタクロリムスの持続送達用ナノリポソーム
JP7041676B2 (ja) 2016-10-28 2022-03-24 レ ラボラトワール セルヴィエ ガンの処置において使用するためのリポソーム製剤
GB2600654B (en) * 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
EP3700506B1 (en) * 2017-10-27 2021-09-08 XYON Health Inc. Topical formulations for treating dermatological disorders including male pattern baldness
MX390288B (es) * 2018-02-06 2025-03-20 Centro Int De Cosmiatria S A P I De C V Formulación y método para el tratamiento de la alopecia androgénica.
WO2020109365A1 (en) * 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
WO2021232054A1 (en) * 2020-05-12 2021-11-18 Chemistryrx Compositions for treating hair loss
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
US11850300B2 (en) 2022-03-17 2023-12-26 Rally Guide Topical lotion composition, methods of use, and methods of preparation
CN121152621A (zh) * 2023-04-14 2025-12-16 北京剂泰生命科技有限公司 脂质纳米颗粒组合物及其用途
WO2025037276A1 (en) * 2023-08-16 2025-02-20 Jina Pharmaceuticals Inc. COMPOSITIONS CONTAINING mTOR INHIBITORS AND LIPIDS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6185312A (ja) * 1984-09-24 1986-04-30 メゼイ・アソシエイツ・リミテッド 多相リポソーム薬剤送達系
JPH0971513A (ja) * 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd 育毛剤
JPH1059829A (ja) * 1996-08-13 1998-03-03 Noevir Co Ltd 養毛剤
JP2001288090A (ja) * 2000-04-07 2001-10-16 Taisho Pharmaceut Co Ltd ミノキシジル含有製剤
JP2002308740A (ja) * 2001-04-05 2002-10-23 Taisho Pharmaceut Co Ltd ミノキシジル含有製剤
JP2003521452A (ja) * 1998-08-04 2003-07-15 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 活性薬剤用の局所的供給システム

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0158441B2 (en) * 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposome-forming composition
US4663167A (en) * 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US4897269A (en) * 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
DE3888994T2 (de) 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
CA1330199C (en) 1987-12-22 1994-06-14 Thomas D. Madden Spontaneous vesiculation of multilamellar liposomes
US5000887A (en) * 1988-05-17 1991-03-19 Liposome Technology, Inc. Preparation of uniform-size liposomes
JP2798302B2 (ja) * 1989-03-31 1998-09-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア リポソームおよび脂質複合体組成物の調製
WO1992003123A1 (en) 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US20040175417A1 (en) 1990-10-19 2004-09-09 Gilead Sciences, Inc. Amphotericin B liposome preparation
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US6733776B1 (en) * 1992-04-02 2004-05-11 Anticancer, Inc. Method for promoting hair growth
US7556825B2 (en) 1993-04-02 2009-07-07 Anticancer, Inc. Method for promoting hair growth
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
US5834014A (en) 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
US6030948A (en) * 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
US6265412B1 (en) 1998-05-26 2001-07-24 Taisho Pharmaceutical Co., Ltd. Minoxidil compositions for external use
JP4444385B2 (ja) * 1999-02-25 2010-03-31 帝人株式会社 リポソーム用時調製用キット
HUP0200483A3 (en) * 1999-03-11 2004-07-28 Fujisawa Pharmaceutical Co Liposome preparations
CA2309373A1 (en) * 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
US6596266B2 (en) * 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
WO2001085142A1 (en) 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
IN188843B (cg-RX-API-DMAC7.html) * 2000-06-22 2002-11-09 Vinod Daftary Gautam Dr
EP1313479A4 (en) 2000-07-19 2005-09-21 W Roy Knowles PREVENTION OF HAIR LOSS
DE10036799A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Neues Mittel zur Behandlung der Haare und der Kopfhaut
SE0100374D0 (sv) * 2001-02-07 2001-02-07 Pharmacia Ab Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
ES2332584T3 (es) * 2001-03-27 2010-02-09 Phares Pharmaceutical Research N.V. Metodo y composicion para solubilizar un compuesto biologicamente activo con baja solubilidad en agua.
WO2003013245A1 (en) * 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
WO2004039817A1 (en) * 2002-10-16 2004-05-13 Neopharm, Inc. Cardiolipin molecules and method of synthesis
WO2004017943A2 (en) * 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
MXPA05003616A (es) * 2002-10-03 2006-01-24 Univ Mississippi Composiciones que comprenden anfotericina b altamente purificada.
JP2004155690A (ja) * 2002-11-05 2004-06-03 Shiseido Co Ltd 養毛剤組成物
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
KR100508019B1 (ko) * 2003-07-19 2005-08-17 한미약품 주식회사 고순도 1-안드로스텐 유도체의 제조 방법
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
CA2566174A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
JP2008511662A (ja) * 2004-08-30 2008-04-17 セレゲン,インコーポレーテッド 損傷組織の修復を促進するためのWntタンパク質を含む馴化培地
MX2007003789A (es) 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
US20060239951A1 (en) * 2005-03-30 2006-10-26 Alexandre Valentin Methods for stimulating hair growth by administering BMPs
JP2006290841A (ja) * 2005-04-14 2006-10-26 Nippon Zettoc Co Ltd 化粧料の製造方法および化粧料
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
EP2029106A2 (en) 2006-06-07 2009-03-04 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
EP2076244B1 (en) * 2006-10-10 2016-12-07 Jina Pharmaceuticals Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
CN101559038B (zh) 2009-05-21 2011-03-16 江苏黄河药业股份有限公司 非那雄胺的固体脂质纳米粒及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6185312A (ja) * 1984-09-24 1986-04-30 メゼイ・アソシエイツ・リミテッド 多相リポソーム薬剤送達系
JPH0971513A (ja) * 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd 育毛剤
JPH1059829A (ja) * 1996-08-13 1998-03-03 Noevir Co Ltd 養毛剤
JP2003521452A (ja) * 1998-08-04 2003-07-15 ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド 活性薬剤用の局所的供給システム
JP2001288090A (ja) * 2000-04-07 2001-10-16 Taisho Pharmaceut Co Ltd ミノキシジル含有製剤
JP2002308740A (ja) * 2001-04-05 2002-10-23 Taisho Pharmaceut Co Ltd ミノキシジル含有製剤

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526483A (ja) * 2012-08-31 2015-09-10 バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー. ポリマーフィナステリドナノ粒子、これを含有する水性組成物、脱毛症を治療するための組成物、前記組成物を調製するための方法、およびその使用
JPWO2015072564A1 (ja) * 2013-11-17 2017-03-16 株式会社 メドレックス 経皮吸収型コロイド液剤
WO2016186157A1 (ja) * 2015-05-19 2016-11-24 株式会社メドレックス 経皮吸収型液剤
JP2020527146A (ja) * 2017-07-12 2020-09-03 サムソン クリニカル プロプライエタリー リミテッド 育毛促進及び脱毛または過剰な毛髪脱落の治療
JP7191927B2 (ja) 2017-07-12 2022-12-19 サムソン クリニカル プロプライエタリー リミテッド 育毛促進及び脱毛または過剰な毛髪脱落の治療
JP2022506944A (ja) * 2018-11-08 2022-01-17 ヴァーソナ セラピューティクス,インコーポレーテッド 5-α-レダクターゼ阻害剤の局所製剤及びそれらの使用

Also Published As

Publication number Publication date
CA2737025A1 (en) 2010-04-01
LT2344198T (lt) 2021-02-25
EP2344198B1 (en) 2020-11-04
SI2344198T1 (sl) 2021-01-29
WO2010036947A2 (en) 2010-04-01
EP2344198A4 (en) 2013-01-09
PL2344198T3 (pl) 2021-05-31
HUE052571T2 (hu) 2021-05-28
MX2011003207A (es) 2011-11-04
CY1123579T1 (el) 2022-03-24
WO2010036947A3 (en) 2010-06-10
JP2017048188A (ja) 2017-03-09
US9750812B2 (en) 2017-09-05
ES2834006T3 (es) 2021-06-16
CA2737025C (en) 2012-09-04
US20110212167A1 (en) 2011-09-01
JP2014221784A (ja) 2014-11-27
DK2344198T3 (da) 2020-11-30
PT2344198T (pt) 2020-12-04
EP2344198A2 (en) 2011-07-20
JP6196943B2 (ja) 2017-09-13
HRP20201860T1 (hr) 2021-04-16

Similar Documents

Publication Publication Date Title
JP6196943B2 (ja) 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用
JP6901421B2 (ja) 半フッ化アルカンを基礎にした局所薬学的組成物
JP6666992B2 (ja) 局所用レチノイド組成物
Pierre et al. Liposomal systems as drug delivery vehicles for dermal and transdermal applications
RU2667010C2 (ru) Способы лечения эпилепсии или эпилептического статуса
CA1333993C (en) Drug carriers
Cosco et al. Colloidal carriers for the enhanced delivery through the skin
EP3137481B1 (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
JP7561629B2 (ja) 不溶性薬物用の水性製剤
JP2012504135A5 (cg-RX-API-DMAC7.html)
Lingan et al. Formulation and evaluation of topical drug delivery system containing clobetasol propionate niosomes
JP2010510327A (ja) エンドキシフェンの方法および組成物
KR100533460B1 (ko) 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
JPH0798740B2 (ja) 薬物担体
JPH0788305B2 (ja) 静脈内投与用組成物およびその製法
JP6632837B2 (ja) 乳化組成物
JPH0341025A (ja) 脂溶性コルチコステロイドの治療効果を改良する方法およびこの方法を実施するための組成物
US20230181464A1 (en) Compositions for delivery of bioactive agents into hair follicles
AU2006323567A1 (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
JP2025506762A (ja) 関節鎮痛用ナノ製剤およびその調製方法並びに用途
CN1287773C (zh) 一种鸦胆子油软胶囊制剂
JP4719355B2 (ja) パルトリシン誘導体の注射可能な薬学的処方物
JP2006249010A (ja) 皮膚外用剤
CN120227380A (zh) 含有黄体酮的药物组合物及应用
BR102016001739A2 (pt) Pharmaceutical composition composing lipid nanoparticles containing clobetasol propionate for topical administration in the treatment of alopecia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120924

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120924

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121002

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20121024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140225